Skip to main content
Reimbursement strategy

Market Access Strategy for Medical Devices in Europe

Strategic recommendations on the topic of market access pathways for medical devices and IVD tests

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MTRC has released a White Paper "Innovation Funding (Forfait Innovation) for Medical Technologies in France”

MTRC has released a White Paper titled "Innovation Funding (Forfait Innovation) for Medical Technologies in France”. Innovative payment schemes are bilateral or multilateral agreements that support medical technologies and procedures that do not fit well with or meet the criteria for the existing reimbursement and funding frameworks.

France is the leading European country in innovative payment schemes supporting evidence generation or early adoption of medical technologies. One such scheme is Innovation Funding (Forfait Innovation) for Medical Technologies, which provides early support for breakthrough innovation and bridges serious evidence gaps simultaneously. Forfait Innovation allows manufacturers to apply to the Ministry of Health and HAS for support of a government-co-sponsored study of novel medical devices, procedures, and IVD tests. 

Our latest White Paper provides a comprehensive overview of the Innovation Funding (Forfait Innovation) program. It describes the scheme’s objectives, eligibility criteria, funding structure, and the decision-making process with regulated timelines. It also outlines the roles of stakeholders, clinical and economic evidence requirements, and the outcomes of applications since the program’s launch in 2015. In addition, this document presents a case study of the METAglut1 test, illustrating the pathway from Innovation Funding to permanent reimbursement inclusion under NABM.

This resource offers manufacturers a clear roadmap for navigating the Innovation Funding framework, securing support for evidence generation, and making a significant step forward with the market access of their cutting-edge medical solutions in France.

Read more and request a White Paper here.